TY - JOUR
T1 - Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes
AU - Kupriyanova, Yuliya
AU - Yurchenko, Iryna
AU - Bobrov, Pavel
AU - Bartels, Frederik
AU - Wierichs, Stefan
AU - Jonuscheit, Marc
AU - Korzekwa, Benedict
AU - Prystupa, Katsiaryna
AU - Schoen, Martin
AU - Mendez, Dania
AU - Trenkamp, Sandra
AU - Burkart, Volker
AU - Wagner, Robert
AU - Schrauwen-Hinderling, Vera
AU - Roden, Michael
AU - German Diabetes Study (GDS) Group
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Introduction The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes.Research design and methods Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58 +/- 12 years, body mass index 30.9 +/- 5.2 kg/m2) were examined before (baseline) and 1 year (12 +/- 2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61 +/- 6 years, 30.0 +/- 4.6 kg/m2).Results COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed.Conclusions History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.Trial registration number NCT01055093.
AB - Introduction The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes.Research design and methods Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58 +/- 12 years, body mass index 30.9 +/- 5.2 kg/m2) were examined before (baseline) and 1 year (12 +/- 2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61 +/- 6 years, 30.0 +/- 4.6 kg/m2).Results COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed.Conclusions History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.Trial registration number NCT01055093.
KW - COVID-19
KW - Diabetes Mellitus, Type 2
KW - MAGNETIC-RESONANCE ELASTOGRAPHY
KW - FATTY LIVER-DISEASE
KW - FIBROSIS
U2 - 10.1136/bmjdrc-2024-004727
DO - 10.1136/bmjdrc-2024-004727
M3 - Article
SN - 2052-4897
VL - 13
JO - BMJ Open Diabetes Research & Care
JF - BMJ Open Diabetes Research & Care
IS - 1
M1 - e004727
ER -